https://images.mktw.net/im-63489829
Last Updated:
First Published:
Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% jump in second-quarter revenue on strength in its Vyndaqel heart medication and its COVID-19 drugs.
Pfizer
PFE increased its 2025 profit outlook by 10 cents a share to a range of $2.90 to $3.10 a share, citing continued cost cuts, a lower tax rate and “confidence” that strength seen in the first half of the year will continue.
This post was originally published on Market Watch
